Literature DB >> 29206345

Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.

Martina Durcik1, Päivi Tammela2, Michaela Barančoková1, Tihomir Tomašič1, Janez Ilaš1, Danijel Kikelj1, Nace Zidar1.   

Abstract

ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes of antibacterial drugs that are unrepresented in the antibacterial pipeline. We developed 32 new N-phenylpyrrolamides and evaluated them against DNA gyrase and topoisomerase IV from E. coli and Staphylococcus aureus. Antibacterial activities were studied against Gram-positive and Gram-negative bacterial strains. The most potent compound displayed an IC50 of 47 nm against E. coli DNA gyrase, and a minimum inhibitory concentration (MIC) of 12.5 μm against the Gram-positive Enterococcus faecalis. Some compounds displayed good antibacterial activities against an efflux-pump-deficient E. coli strain (MIC=6.25 μm) and against wild-type E. coli in the presence of efflux pump inhibitor PAβN (MIC=3.13 μm). Here we describe new findings regarding the structure-activity relationships of N-phenylpyrrolamide DNA gyrase B inhibitors and investigate the factors that are important for the antibacterial activity of this class of compounds.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  DNA gyrase; GyrB; antibacterials; inhibitors; pyrrolamides

Mesh:

Substances:

Year:  2018        PMID: 29206345     DOI: 10.1002/cmdc.201700549

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  New N-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors.

Authors:  Nace Zidar; Helena Macut; Tihomir Tomašič; Lucija Peterlin Mašič; Janez Ilaš; Anamarija Zega; Päivi Tammela; Danijel Kikelj
Journal:  Medchemcomm       Date:  2019-05-20       Impact factor: 3.597

2.  Design, Synthesis, and Antibacterial Screening of Some Novel Heteroaryl-Based Ciprofloxacin Derivatives as DNA Gyrase and Topoisomerase IV Inhibitors.

Authors:  Lamya H Al-Wahaibi; Amer A Amer; Adel A Marzouk; Hesham A M Gomaa; Bahaa G M Youssif; Antar A Abdelhamid
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-22

3.  Induction of Antibacterial Metabolites by Co-Cultivation of Two Red-Sea-Sponge-Associated Actinomycetes Micromonospora sp. UR56 and Actinokinespora sp. EG49.

Authors:  Mohamed S Hifnawy; Hossam M Hassan; Rabab Mohammed; Mohamed M Fouda; Ahmed M Sayed; Ahmed A Hamed; Sameh F AbouZid; Mostafa E Rateb; Hani A Alhadrami; Usama Ramadan Abdelmohsen
Journal:  Mar Drugs       Date:  2020-05-05       Impact factor: 5.118

4.  Bioactive secondary metabolites from marine Actinomyces sp. AW6 with an evaluation of ADME-related physicochemical properties.

Authors:  Mohamed A Agour; Ahmed A Hamed; Mosad A Ghareeb; Eman A A Abdel-Hamid; Mohamed K Ibrahim
Journal:  Arch Microbiol       Date:  2022-08-01       Impact factor: 2.667

5.  Discovery of Two Brominated Oxindole Alkaloids as Staphylococcal DNA Gyrase and Pyruvate Kinase Inhibitors via Inverse Virtual Screening.

Authors:  Ahmed M Sayed; Hani A Alhadrami; Seham S El-Hawary; Rabab Mohammed; Hossam M Hassan; Mostafa E Rateb; Usama Ramadan Abdelmohsen; Walid Bakeer
Journal:  Microorganisms       Date:  2020-02-20

6.  New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.

Authors:  Martina Durcik; Denise Lovison; Žiga Skok; Cristina Durante Cruz; Päivi Tammela; Tihomir Tomašič; Davide Benedetto Tiz; Gábor Draskovits; Ákos Nyerges; Csaba Pál; Janez Ilaš; Lucija Peterlin Mašič; Danijel Kikelj; Nace Zidar
Journal:  Eur J Med Chem       Date:  2018-05-10       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.